Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case–control studies in hospitalized patients
Introduction
Pseudomonas aeruginosa is a leading cause of nosocomial infection, particularly pneumonia, according to recent surveillance reports.1, 2 This organism is also involved in urinary, wound and bloodstream infections. Infections due to P. aeruginosa are difficult to treat because of the limited therapeutic options, and are usually associated with high mortality despite the use of appropriate therapy.3, 4 The resistance of P. aeruginosa to imipenem has been reported worldwide5, 6, 7 and is often associated with resistance to other antipseudomonal drugs.8, 9
Inadequate empirical antimicrobial therapy is associated with adverse outcomes,10, 11, 12, 13 and the identification of risk factors for antimicrobial resistance in P. aeruginosa could guide clinicians in their empirical therapeutic options for individual patients. The identification of risk factors may also lead to changes in antibiotic-prescribing patterns, with a decrease in bacterial resistance and improvement of outcome for these patients.14
Previous studies have examined risk factors for antimicrobial resistance with emphasis on the control group selection.14, 15, 16 The aim of the present study was to identify clinically significant risk factors for acquiring imipenem-resistant P. aeruginosa, and to assess risk factors reported previously using a comparative approach of two case–control studies with distinct control groups.
Section snippets
Methods
Two case–control studies were performed concurrently at Hospital São Lucas, a 600-bed tertiary care teaching hospital. All patients who had nosocomial P. aeruginosa isolated from any site between 1 September 2002 and 1 July 2003 were included in the study. In Study 1, case patients were those with imipenem-resistant P. aeruginosa (IRPA) and control patients were selected at random from patients hospitalized in the same unit by means of computer-generated random numbers. In Study 2, cases were
Results
In total, 189 P. aeruginosa isolates were identified by the microbiology laboratory. Ten were excluded because they were isolated from patients within 48 h of hospital admission, and 16 because they were isolated from patients with previous IRPA (N=4) or ISPA (N=12). Five patients who were initially selected as controls in Study 2 yielded IRPA and were transferred to the case groups. Two patients initially selected as controls in Study 1 had IRPA and ISPA and were transferred to the case group
Discussion
The present study assessed potential risk factors for IRPA in hospital patients. We performed two studies with distinct control groups for better understanding of the association of the variables with the outcome.
In studying risk factors for the isolation of nosocomial-resistant bacteria, control patients selected from the same unit as the case patients are considered to be the most suitable.14, 15, 16, 20 However, this design cannot differentiate whether the variable analysed is a risk factor
Acknowledgements
We thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Ministry of Education of Brazil for financial support; Dr Luis Fernando Rodrigues, Cláudia Meirelles Leite and Fabiana Correa Soares for microbiology laboratory support; Dr Mario B. Wagner for statistical analysis; and Andrea Escobar Dias for database management.
References (25)
- et al.
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)
Diagn Microbiol Infect Dis
(2003) - et al.
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000)
Diagn Microbiol Infect Dis
(2002) - et al.
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients
Am J Med
(1989) - et al.
Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy
Int J Infect Dis
(1998) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Epidemiological study of variations in β-lactam antibiotic susceptibility of Pseudomonas aeruginosa in two intensive care units
J Hosp Infect
(1997) Clinical problems posed by multiresistant nonfermenting Gram-negative pathogens
Clin Infect Dis
(1998)Prescribing guidelines for severe Pseudomonas infections
J Antimicrob Chemother
(2002)National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992–June, issued August 2001
Am J Infect Control
(2001)- et al.
Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001)
J Antimicrob Chemother
(2003)
Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY participants
Eur J Clin Microbiol Infect Dis
Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns
Clin Infect Dis
Cited by (66)
Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa
2018, Journal of Microbiology, Immunology and InfectionCitation Excerpt :In addition, only patients who were confirmed to have HAI caused by P. aeruginosa were included in this study to avoid the bias that might be caused by patients with colonization. Several studies have reported that risk factors associated with CRPA acquisition are the presence of multiple comorbidities, length of hospitalization, receiving invasive procedures and prior use of antibiotics.10–17 Consistent with many other studies,11–13,18 there was a positive correlation between the length of hospitalization stays prior to CRPA confirmation and the rate of CRPA contraction.
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems
2017, Journal of Microbiology, Immunology and InfectionCiprofloxacin and imipenem resistance and cross-resistance in Pseudomonas aeruginosa: A single institution experience
2016, American Journal of Infection Control